

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



December 1, 2025

To whom it may concern:

Company name	KISSEI PHARMACEUTICAL CO., LTD.
Representative	Mutsuo Kanzawa, Chairman and CEO (Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact	Takahide Kitahara, Managing Director, Department Manager of Corporate Finance and Management Department, CFO (Telephone +81-263-25-9081)

### Notice of Change to Scheduled Date to Commence Dividend Payments

KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that at the Board of Directors meeting held on December 1, 2025, the Company has resolved to change the scheduled date(effective date) to commence dividend payments for interim dividends with a record date of September 30, 2025 to December 2, 2025. Accordingly, part of the description in the “Consolidated Financial Results for the Six Months Ended September 30, 2025 [Japanese GAAP]” disclosed on November 4, 2025 will change as follows.

1. Details of revision (underlined section changed)

Consolidated Financial Results for the Six Months Ended September 30, 2025 [Japanese GAAP] 1<sup>st</sup> page of the Summary

(Before the change) Scheduled date of commencing dividend payments: December 3, 2025

(After the change) Scheduled date of commencing dividend payments: December 2, 2025

Please note that there is no change to the dividend per share of 60.00 yen.

2. Reason for change

To readjust administrative procedures relating to the payment of dividends.

-End-